Similar articles

• Global Overview of the Transnational Alliance for Regenerative Therapies in Cardiovascular Syndromes (TACTICS) Recommendations: A Comprehensive Series of Challenges and Priorities of Cardiovascular Regenerative Medicine.

  Fernández-Avilés F, Sanz-Ruiz R, Climent AM, Badimon L, Bolli R, Charron D, Fuster V, Janssens S, Kastrup J, Kim HS, Lüscher TF, Martin JF, Menasché P, Pinto FJ, Simari RD, Stone GW, Terzic A, Willerson JT, Wu JC; TACTICS Writing Group. Fernández-Avilés F, et al. Circ Res. 2018 Jan 19;122(2):199-201. doi: 10.1161/CIRCRESAHA.117.312099. Circ Res. 2018. PMID: 29348246 No abstract available.
• [Cardiovascular regenerative medicine at the crossroads. Clinical trials of cellular therapy must now be based on reliable experimental data from animals with characteristics similar to human's].

  Nadal-Ginard B, Torella D, Ellison G. Nadal-Ginard B, et al. Rev Esp Cardiol. 2006 Nov;59(11):1175-89. Rev Esp Cardiol. 2006. PMID: 17144992 Review. Spanish.
• Caution urged in trial of stem cells to treat spinal-cord injury.

  Barde Y. Barde Y. Nature. 2009 Mar 5;458(7234):29. doi: 10.1038/458029a. Nature. 2009. PMID: 19262651 No abstract available.
• Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program.

  Jones LC, Dhruva SS, Redberg RF. Jones LC, et al. JAMA Intern Med. 2018 Oct 1;178(10):1418-1420. doi: 10.1001/jamainternmed.2018.3649. JAMA Intern Med. 2018. PMID: 30178044 Free PMC article.
• A Path Forward for Regenerative Medicine.

  Fanaroff AC, Morrow V, Krucoff MW, Seltzer JH, Perin EC, Taylor DA, Miller LW, Zeiher AM, Fernández-Avilés F, Losordo DW, Henry TD, Povsic TJ. Fanaroff AC, et al. Circ Res. 2018 Aug 3;123(4):495-505. doi: 10.1161/CIRCRESAHA.118.313261. Circ Res. 2018. PMID: 30355250 Review.